Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report
- PMID: 30349718
- PMCID: PMC6186889
- DOI: 10.1002/ccr3.1790
Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report
Abstract
Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.
Keywords: bleomycin; infliximab; intensive care; pulmonary toxicity; respiratory failure; treatment outcome.
Figures
References
-
- Sleijfer S. Bleomycin‐induced pneumonitis. Chest. 2001;120(2):617‐624. - PubMed
-
- Bleomycin product information document submitted to Therapeutic Goods of Australia, Aspen Pharma Pty Ltd, Published on June 26, 2006. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&i.... Accessed June 24, 2018.
-
- Reinert T, Serodio da Rocha Baldotto C, Pereira Nunes F, Alves de Souza Scheliga A. Bleomycin‐induced lung injury. J Cancer Res. 2013;480608:9.
-
- Brugge SS, Claasen HR, Dawson L. Drug induced lung injury‐a case of fatal Bleomycin interstitial pneumonitis. Netherlands J Critical Care. 2013;17:25‐29.
Publication types
LinkOut - more resources
Full Text Sources